Skip to main content
. 2015 Dec 31;5(1):31–44. doi: 10.1007/s40121-015-0099-1

Fig. 3.

Fig. 3

Comparing observed data (a) with simulations of adding residual disease over time (b); with fixed reduction in RV-positive tests without residual disease (c); vaccine waning (−10% per year) (d); changing vaccine coverage rate (85% to 65%) (e). Nbr number, RV rotavirus